Rain Oncology (NASDAQ:RAIN) Stock Rating Lowered by Lifesci Capital

Lifesci Capital cut shares of Rain Oncology (NASDAQ:RAIN – Get Rating) from an outperform rating to a market perform rating in a report issued on Monday morning, PriceTargets.com reports. Several other equities analysts have also commented on the company. EF Hutton Acquisition Co. I reaffirmed a buy rating and issued a $16.00 price target on […]

Related Keywords

United States , ,Samsara Biocapital ,Ef Hutton Acquisition Co ,Monashee Investment Management ,Rain Oncology Company Profile ,Rain Therapeutics Inc ,Citigroup ,Capital Corp ,Boxer Capital ,Boxer Capital Llc ,Sectoral Asset Management Inc ,Lifesci Capital ,Rain Oncology ,Get Rating ,Roth Capital ,Oncology Stock Down ,Asset Management ,Therapeutics Inc ,Rain Oncology Daily ,Nasdaq Rain ,Rain ,Medical ,Downgrade ,